CN1914212B - Gabaa激动剂的多晶型 - Google Patents

Gabaa激动剂的多晶型 Download PDF

Info

Publication number
CN1914212B
CN1914212B CN2005800031615A CN200580003161A CN1914212B CN 1914212 B CN1914212 B CN 1914212B CN 2005800031615 A CN2005800031615 A CN 2005800031615A CN 200580003161 A CN200580003161 A CN 200580003161A CN 1914212 B CN1914212 B CN 1914212B
Authority
CN
China
Prior art keywords
gaboxadol
monohydrate
disorder
compound
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN2005800031615A
Other languages
English (en)
Chinese (zh)
Other versions
CN1914212A (zh
Inventor
V·B·库珀
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31971783&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1914212(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Publication of CN1914212A publication Critical patent/CN1914212A/zh
Application granted granted Critical
Publication of CN1914212B publication Critical patent/CN1914212B/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN2005800031615A 2004-01-30 2005-01-28 Gabaa激动剂的多晶型 Expired - Lifetime CN1914212B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0402118.4A GB0402118D0 (en) 2004-01-30 2004-01-30 Polymorphic forms of a GABAA agonist
GB0402118.4 2004-01-30
PCT/GB2005/000288 WO2005073237A2 (en) 2004-01-30 2005-01-28 Polymorphic forms of a gabaa agonist

Publications (2)

Publication Number Publication Date
CN1914212A CN1914212A (zh) 2007-02-14
CN1914212B true CN1914212B (zh) 2010-10-06

Family

ID=31971783

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2005800031615A Expired - Lifetime CN1914212B (zh) 2004-01-30 2005-01-28 Gabaa激动剂的多晶型

Country Status (34)

Country Link
US (2) US7262300B2 (enExample)
EP (2) EP2042505A1 (enExample)
JP (1) JP4917440B2 (enExample)
KR (1) KR101210361B1 (enExample)
CN (1) CN1914212B (enExample)
AR (1) AR047511A1 (enExample)
AT (1) ATE414088T1 (enExample)
AU (1) AU2005209473B2 (enExample)
BR (1) BRPI0506858A (enExample)
CA (1) CA2554536C (enExample)
CO (1) CO5700743A2 (enExample)
CY (1) CY1108647T1 (enExample)
DE (1) DE602005010975D1 (enExample)
DK (1) DK1713813T3 (enExample)
DO (1) DOP2005000013A (enExample)
EA (1) EA009413B1 (enExample)
EC (1) ECSP066735A (enExample)
ES (1) ES2314613T3 (enExample)
GB (2) GB0402118D0 (enExample)
HR (1) HRP20080614T3 (enExample)
IL (1) IL176863A0 (enExample)
MA (1) MA28364A1 (enExample)
MX (1) MXPA06008595A (enExample)
MY (1) MY139525A (enExample)
NO (1) NO20063843L (enExample)
NZ (1) NZ548191A (enExample)
PE (1) PE20050769A1 (enExample)
PL (1) PL1713813T3 (enExample)
PT (1) PT1713813E (enExample)
SI (1) SI1713813T1 (enExample)
TW (1) TWI345972B (enExample)
UA (1) UA87487C2 (enExample)
WO (1) WO2005073237A2 (enExample)
ZA (1) ZA200605307B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
US8268866B2 (en) 2004-03-29 2012-09-18 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US20060063802A1 (en) 2004-03-29 2006-03-23 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US9072662B2 (en) 2004-03-29 2015-07-07 Auris Medical Ag Methods for the treatment of tinnitus induced by cochlear excitotoxicity
DE102005004343A1 (de) * 2005-01-25 2006-08-10 Eberhard-Karls-Universität Tübingen Universitätsklinikum Behandlung von Phantomphänomenen
EP1848420A4 (en) 2005-01-28 2008-01-23 Merck & Co Inc POLYMORPH SHAPES OF A GABAA AGONIST
BRPI0520588B8 (pt) 2005-09-28 2021-05-25 Auris Medical Ag uso de composições farmacêuticas para o tratamento de doenças do ouvido interno
CN102093387B (zh) * 2009-12-10 2012-07-25 天津泰普医药知识产权流转储备中心有限公司 4,5,6,7-四氢异噁唑并[5,4-c]吡啶-3-醇一水合物的晶型化合物
WO2013087090A1 (en) 2011-12-12 2013-06-20 Auris Medical Ag Treatment of tinnitus through modulation of chloride co-transporter nkcc1 in the auditory system
MX391708B (es) 2015-07-17 2025-03-21 Ovid Therapeutics Inc Metodos para tratar trastornos del desarrollo con gaboxadol.
MX2019001669A (es) 2016-08-11 2019-09-27 Ovid Therapeutics Inc Metodos y composiciones para el tratamiento de trastornos epilepticos.
AU2017363598A1 (en) * 2016-11-22 2019-05-23 Ovid Therapeutics Inc. Methods of treating developmental disorders and/or seizure disorders with flupirtine
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
KR20200047557A (ko) 2017-08-04 2020-05-07 오비드 테라퓨틱스 인크. 당뇨병 및 관련 질환들의 치료에서 가복사돌의 사용
KR20210062662A (ko) 2018-09-20 2021-05-31 오비드 테라퓨틱스 인크. 투렛 증후군, 틱들 및 말더듬의 치료를 위한 가복사돌의 사용
CN113395962A (zh) 2018-11-21 2021-09-14 Certego治疗公司 加波沙朵用于降低自杀风险和快速缓解抑郁症
WO2020131856A1 (en) 2018-12-17 2020-06-25 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder
AU2020405060A1 (en) 2019-12-18 2022-06-09 Ovid Therapeutics Inc. Gaboxadol for therapeutic treatment of 1p36 deletion syndrome
AU2021275863A1 (en) 2020-05-20 2023-02-02 Certego Therapeutics Inc. Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0000338A2 (en) * 1977-06-20 1979-01-24 H.Lundbeck & Co., A/S Isoxazolo(5,4-c)pyridine derivatives, their preparation and pharmaceutical compositions containing them

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4315934A (en) * 1979-09-24 1982-02-16 Sandoz Ltd. Organic compounds
US4362731A (en) 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4352731A (en) * 1980-11-03 1982-10-05 Occidental Research Corporation Apparatus for selective wetting of particles
DE19525598C2 (de) 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
UA52661C2 (uk) * 1996-06-14 2003-01-15 Ново Нордіск А/С Безводна кристалічна форма гідрохлориду r(-)-n-(4,4-ди(3-метилтієн-2-іл)бут-3-еніл) ніпекотинової кислоти
WO2001022941A1 (en) 1999-09-28 2001-04-05 H. Lundbeck A/S Melt granulated composition and modified release dosage form prepared from said composition
AR031473A1 (es) 2000-11-20 2003-09-24 Lundbeck & Co As H Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide
MXPA03010610A (es) 2001-05-18 2004-04-02 Lonza Ag Metodo para la preparacion de formulaciones solidas de 3-hidroxi-3-metilbutirato de sodio.
CZ20033269A3 (en) 2001-05-21 2004-03-17 H. Lundbeck A/S Granular preparations of gaboxadol
AU2002333157A1 (en) * 2002-09-03 2004-03-29 Naturon Limited Compound for treatment of anxiety and methods of preparation and use thereof
US20050234093A1 (en) * 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
EP2145620A3 (en) 2003-06-25 2010-03-17 H. Lundbeck A/S Gaboxadol for treating depression and other affective disorders
AR045540A1 (es) * 2003-09-05 2005-11-02 Lundbeck & Co As H Metodo de elaboracion de 4,5,6,7 tetrahidroisoxazol [5,4-c] piridin-3-ol (thip)
EP1663218A1 (en) 2003-09-10 2006-06-07 MERCK SHARP & DOHME LTD. Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome
TW200528098A (en) 2003-12-18 2005-09-01 Lundbeck & Co As H Treatment of insomnia in human patients
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
CA2572302A1 (en) 2004-06-29 2006-05-26 H. Lundbeck A/S Treatment of neuropathic pain, fibromyalgia or rheumatoid arthritis
GB0417558D0 (en) 2004-08-06 2004-09-08 Merck Sharp & Dohme Novel combination therapy
EP1848420A4 (en) * 2005-01-28 2008-01-23 Merck & Co Inc POLYMORPH SHAPES OF A GABAA AGONIST
EP1863808A1 (en) 2005-03-18 2007-12-12 Transform Pharmaceuticals, Inc. Gaboxadol forms, compositions thereof, and related methods
EP1906953A4 (en) 2005-04-29 2009-05-20 Lundbeck & Co As H ACID AND BASE SALT FORMS OF GABOXADOL

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0000338A2 (en) * 1977-06-20 1979-01-24 H.Lundbeck & Co., A/S Isoxazolo(5,4-c)pyridine derivatives, their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
DOP2005000013A (es) 2005-08-15
HK1096547A1 (en) 2007-06-01
NZ548191A (en) 2010-04-30
PE20050769A1 (es) 2005-10-04
HRP20080614T3 (en) 2009-01-31
US20070259912A1 (en) 2007-11-08
SI1713813T1 (sl) 2009-02-28
PL1713813T3 (pl) 2009-04-30
KR101210361B1 (ko) 2012-12-10
MY139525A (en) 2009-10-30
TWI345972B (en) 2011-08-01
CN1914212A (zh) 2007-02-14
CY1108647T1 (el) 2014-04-09
GB0501847D0 (en) 2005-03-09
US7262300B2 (en) 2007-08-28
EA200601404A1 (ru) 2006-12-29
ZA200605307B (en) 2007-11-28
CA2554536C (en) 2012-09-18
JP4917440B2 (ja) 2012-04-18
PT1713813E (pt) 2008-12-26
WO2005073237A3 (en) 2005-10-20
BRPI0506858A (pt) 2007-05-29
UA87487C2 (ru) 2009-07-27
EA009413B1 (ru) 2007-12-28
ECSP066735A (es) 2006-10-31
EP2042505A1 (en) 2009-04-01
IL176863A0 (en) 2006-10-31
CO5700743A2 (es) 2006-11-30
KR20070007070A (ko) 2007-01-12
MXPA06008595A (es) 2006-08-28
AU2005209473B2 (en) 2010-03-04
MA28364A1 (fr) 2006-12-01
NO20063843L (no) 2006-08-29
US20050171142A1 (en) 2005-08-04
EP1713813A2 (en) 2006-10-25
JP2007519697A (ja) 2007-07-19
TW200534856A (en) 2005-11-01
US8236958B2 (en) 2012-08-07
WO2005073237A2 (en) 2005-08-11
DE602005010975D1 (de) 2008-12-24
EP1713813B1 (en) 2008-11-12
AR047511A1 (es) 2006-01-25
GB2410434A (en) 2005-08-03
ES2314613T3 (es) 2009-03-16
ATE414088T1 (de) 2008-11-15
GB0402118D0 (en) 2004-03-03
CA2554536A1 (en) 2005-08-11
DK1713813T3 (da) 2009-02-16
AU2005209473A1 (en) 2005-08-11

Similar Documents

Publication Publication Date Title
US8236958B2 (en) Polymorphic forms of a GABAA agonist
JP5701246B2 (ja) 有機化合物
JP2015134785A (ja) ナルメフェン塩酸塩二水和物
US8193216B2 (en) Polymorphic forms of a GABAA agonist
US20030191347A1 (en) Venlafaxine base
HUP0303154A2 (hu) Az oxkarbazepin új kristályformái, és az előállításukra szolgáló eljárások
WO2006087732A1 (en) An amorphous and three crystalline forms of rimonabant hydrochloride
HK1096547B (en) Polymorphic forms of a gabaa agonist
WO2014023027A1 (zh) 盐酸埃罗替尼多晶型物及其制备方法
JP2002507215A (ja) ５−（２−エチル−２ｈ−テトラゾール−５−イル）−１−メチル−１，２，３，６−テトラヒドロピリジン マレイン酸塩

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: LUNDBECK + CO. AS H.

Free format text: FORMER OWNER: MERCK SHARP + DOHME

Effective date: 20090911

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20090911

Address after: Copenhagen, Denmark

Applicant after: H. LUNDBECK A/S

Address before: Hertfordshire

Applicant before: MERCK SHARP & DOHME LTD.

C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term

Granted publication date: 20101006

CX01 Expiry of patent term